Nisa Investment Advisors LLC Has $1.13 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Nisa Investment Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 14,674.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,160 shares of the specialty pharmaceutical company’s stock after buying an additional 9,098 shares during the period. Nisa Investment Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $1,127,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of JAZZ. US Bancorp DE raised its position in Jazz Pharmaceuticals by 13.3% during the first quarter. US Bancorp DE now owns 2,736 shares of the specialty pharmaceutical company’s stock valued at $427,000 after buying an additional 322 shares during the period. Private Advisor Group LLC acquired a new position in Jazz Pharmaceuticals in the 1st quarter worth about $547,000. Aviva PLC increased its position in Jazz Pharmaceuticals by 87.1% in the 1st quarter. Aviva PLC now owns 40,005 shares of the specialty pharmaceutical company’s stock worth $6,228,000 after purchasing an additional 18,628 shares during the last quarter. Allianz Asset Management GmbH increased its position in Jazz Pharmaceuticals by 118.2% in the 1st quarter. Allianz Asset Management GmbH now owns 12,130 shares of the specialty pharmaceutical company’s stock worth $1,888,000 after purchasing an additional 6,571 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Jazz Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 5,602,650 shares of the specialty pharmaceutical company’s stock worth $872,164,000 after purchasing an additional 57,949 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Stifel Nicolaus upped their target price on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $180.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. UBS Group decreased their price target on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating for the company in a research note on Friday, March 1st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $220.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $195.08.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $110.91 on Tuesday. The business has a 50 day moving average price of $120.99 and a 200 day moving average price of $122.95. Jazz Pharmaceuticals plc has a twelve month low of $110.08 and a twelve month high of $146.70. The company has a market cap of $6.99 billion, a price-to-earnings ratio of 18.12, a PEG ratio of 1.53 and a beta of 0.59. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. Research analysts predict that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Jazz Pharmaceuticals news, CFO Philip L. Johnson purchased 12,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was purchased at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Patricia Carr sold 1,936 shares of the stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares in the company, valued at $1,000,668.96. The disclosure for this sale can be found here. Corporate insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.